TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6313028
Drug: Theophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (6 mg/kg) while supine
Study: 6313028
Drug: Theophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (6 mg/kg) while standing vs supine
Study: 29359722
Drug: Standard infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard infusion therapy (Control)
Study: 24965957
Drug: Pilates method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates method with NSAID treatment
Study: 24965957
Drug: NSAID treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID treatment without Pilates
Study: 23818768
Drug: Daily antioxidant
Normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antioxidant and essential polyunsaturated fatty acid supplement (two pills) for 3 months (+S)
Study: 11720628
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical and surgical therapy
Study: 7048915
Drug: Acyclovir applied
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir applied topically four times daily for 10 days
Study: 7048915
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied topically four times daily for 10 days
Study: 24184576
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered oxytocin (16 IU)
Study: 22044433
Drug: Flupirtine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (400 mg/day, titrated to 600 mg/day)
Study: 22044433
Drug: Tolterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (4 mg/day)
Study: 18199844
Drug: CAPD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPD with a target creatinine clearance > or =60 L/wk/1.73 m(2)
Study: 8627061
Drug: Interferon alfa‐n3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐n3 (IFN‐alpha n3) 1 mega‐IU (MIU)/dose
Study: 8627061
Drug: Interferon alfa‐n3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐n3 (IFN‐alpha n3) 5 MIU/dose
Study: 8627061
Drug: Interferon alfa‐n3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐n3 (IFN‐alpha n3) maximum tolerated dose
Study: 1471382
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pantoprazole o.m.
Study: 1471382
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole o.m.
Study: 1471382
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg pantoprazole o.m.
Study: 20108156
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% bupivacaine (50 mg)
Study: 20108156
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of sterile water
Study: 15641037
Drug: Cisplatin 70
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 70 mg/m2 on Day 1, etoposide 50 mg/m2 on Days 1-3, and gemcitabine 1000 mg/m2 on Days 1 and 8 (PEG)
Study: 15641037
Drug: Cisplatin 70
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 70 mg/m2 on Day 1 plus gemcitabine 1250 mg/m2 on Days 1 and 8 (PG)
Study: 15553066
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with ribavirin
Study: 15553066
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with PEG-IFN-s
Study: 10470391
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of droperidol
Study: 8759084
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg warfarin
Study: 8759084
Drug: Conventional warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional warfarin therapy
Study: 25854786
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy + Coenzyme Q10 (CoQ10)
Study: 11584209
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate solution (0.025 mg/kg)
Study: 10561250
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m(2) IV over 15 minutes) and docetaxel (75 mg/m(2) IV over 1 hour) every 14 days for four cycles
Study: 2689679
Drug: Vincristine 2
Normalized name: vinCRIStine 2 mg/2 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 2 mg or vindesine 3 mg per week, prednisolone 20 to 30 mg per day, and partly 6-mercaptopurine 50 to 100 mg, combined with allopurinol 200 to 300 mg per day for 2 to 3 weeks.
Study: 2689679
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with busulfan or other alkylating agents.
Study: 5677210
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with tolbutamide, chlorpropamide, or metformin
Study: 28755104
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine (84 mg)
Study: 24678955
Drug: Darapladib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib (160 mg once daily)
Study: 15792400
Drug: New 625
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 625 mg nelfinavir tablet (test formulation)
Study: 15792400
Drug: Commercial 250
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial 250 mg nelfinavir tablet (reference formulation)
Study: 12851606
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with or without abciximab
Study: 2196670
Drug: norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norfloxacin 200 mg twice daily for 7 days
Study: 2196670
Drug: pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 200 mg 3 times daily for 7 days
Study: 351715
Drug: Dopamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine and prostaglandin A1 administered conjointly
Study: 28668289
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 25 μg every 2 h (maximum of 12 doses)
Study: 28668289
Drug: Transcervical Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical Foley catheter (silicone, size 18 F with 30 mL balloon)
Study: 23828223
Drug: HQK-1001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 at 30 mg/kg
Study: 23828223
Drug: HQK-1001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 at 40 mg/kg
Study: 23828223
Drug: HQK-1001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 at 50 mg/kg
Study: 22859239
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg at weeks 0, 4, and 16
Study: 12596623
Drug: One-dose azithromycin
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose azithromycin prophylaxis
Study: 8127110
Drug: Diltiazem (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.1 mg/kg per hour)
Study: 2567150
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg daily for months 0‐6, then 200 mg daily)
Study: 26545986
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering (target LDL cholesterol <1.4 mmol/L)
Study: 26545986
Drug: Guideline lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline lipid lowering (target LDL cholesterol <3 mmol/L)
Study: 3521245
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline solution)
Study: 22475305
Drug: G‐CSF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 10 μg/kg/day for 3 days
Study: 22475305
Drug: Non-G‐CSF group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-G‐CSF group
Study: 17165082
Drug: Verapamil hydrochloride
Normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil hydrochloride (isoptin 240 mg KKH tablets, oral t.i.d.)
Study: 12174946
Drug: Sequential Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Doxorubicin (A) -> Docetaxel (T) -> CMF
Study: 12174946
Drug: Sequential accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential accelerated A -> T -> CMF
Study: 12174946
Drug: Combination therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy: A 50 mg/m2 + T 75 mg/m2 q 3 wks x 4, followed by CMF x 4
Study: 12174946
Drug: Sequential T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential T -> A -> CMF
Study: 8655009
Drug: Antinuclear antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinuclear antibodies (ANA) detected in women with endometriosis
Study: 8655009
Drug: Antinuclear antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinuclear antibodies (ANA) detected in women with idiopathic infertility
Study: 8655009
Drug: Antinuclear antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinuclear antibodies (ANA) detected in women with hypothalamic‐pituitary dysfunction
Study: 8655009
Drug: Antinuclear antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinuclear antibodies (ANA) detected in healthy nonpregnant women
Study: 7433479
Drug: Cinnarizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (75 mg 3-times daily)
Study: 31753880
Drug: Mindful Eating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Eating (ME) + Treatment as Usual (TAU)
Study: 25765294
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% solution twice daily for 3 months
Study: 25765294
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% cream once daily for 3 months
Study: 23389755
Drug: gabapentin (GBP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin (GBP; up to 1,200 mg for 39 days) and flumazenil (FMZ) infusions (2 days)
Study: 20008239
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies and dose‐intensified approaches including autologous stem cell transplantation (ASCT) strategies
Study: 20008239
Drug: Emerging strategies
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging strategies such as proteasome inhibitors, IMIDs, mTOR inhibitors
Study: 20008239
Drug: Combination strategies
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination strategies currently being investigated in numerous trials
Study: 18041162
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and/or ARBs
Study: 9164362
Drug: Ipratropium nasal
Normalized name: ipratropium nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium nasal spray (42 micrograms per nostril, administered twice daily for 4 weeks)
Study: 9164362
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (administered twice daily for 4 weeks)
Study: 3652627
Drug: Deferoxamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine therapy (1 to 6 g intravenously once a week for a mean duration of 7.6 +/- 3.3 months)
Study: 3652627
Drug: Deferoxamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine therapy
Study: 20598832
Drug: Integrated Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive Behavioral Therapy (ICBT)
Study: 23583219
Drug: Digoxin antibody
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin antibody fragment (DIF)
Study: 15673100
Drug: 6% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate-electrolyte (CHO-E) solution
Study: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion (137.5 mum)
Study: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion (137.5 mum) with NOS inhibition (10 mm l-NAME)
Study: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion (137.5 mum) with COX inhibition (10 mm ketorolac)
Study: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion (137.5 mum) with NOS and COX inhibition
Study: 7864705
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 1.2 g over 20 minutes after albuterol treatment
Study: 6185343
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of methotrexate (MTX) 500 mg over 10 days
Study: 6185343
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of bleomycin (BLM) 95 mg over 13 days
Study: 30613078
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity ultrasound (LIUS) and traditional exercise therapy (TET)
Study: 30613078
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) and traditional exercise therapy (TET)
Study: 30613078
Drug: Traditional exercise
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional exercise therapy (TET)
Study: 25074351
Drug: ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibandronate 150 mg/month
Study: 25074351
Drug: alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 70 mg/week
Study: 25074351
Drug: risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risedronate 35 mg/week
Study: 25074351
Drug: oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral bisphosphonates (all three types)
Study: 19885413
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants (thin mucosa, group A)
Study: 19885413
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants (thick mucosa, group B)
Study: 10723632
Drug: Flumazenil 2
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 2 mg/20 ml
Study: 10723632
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo infusions
Study: 8704691
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue
Study: 6361558
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (3 mg/kg initial dose)
Study: 25029202
Drug: Calcitriol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (2 μg intravenously)
Study: 20385996
Drug: Short-course intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course intensive polychemotherapy (in blocks R1, R2, or R3) and cranial/craniospinal irradiation followed by maintenance therapy.
Study: 17288680
Drug: Aspirin 30-325
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 30-325 mg daily
Study: 2273193
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg riboflavin daily
Study: 2273193
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg riboflavin daily
Study: 2273193
Drug: 1.7 mg
Normalized name: pectin 1.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 mg riboflavin (one-a-day supplement)
Study: 31618905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BB536 and AHCC®
Study: 21888870
Drug: Zednad® Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zednad® Tablet (500 mg cefuroxime/tablet)
Study: 21888870
Drug: Zinnat® Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinnat® Tablet (500 mg cefuroxime/tablet)
Study: 19055515
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aspirin
Study: 19055515
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin combined groups
Study: 19055515
Drug: Aspirin groups
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin groups (without considering dose)
Study: 16738974
Drug: Antiemetic drugs
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiemetic drugs (groups 1 to 6)
Study: 1550911
Drug: Intravenous levoprotiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levoprotiline (15 mg)
Study: 1550911
Drug: Peroral levoprotiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral levoprotiline (75 mg)
Study: 3933019
Drug: cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream containing l‐cysteine, glycine and dl‐threonine
Study: 3933019
Drug: cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream base alone (placebo)
Study: 30967424
Drug: Low-dose anti-thymocyte
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg)
Study: 27556735
Drug: Modeling counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modeling counts of golden eagles using distance sampling and visual mark-recapture procedures; no specific dosage or duration mentioned as this is observational modeling.
Study: 27556735
Drug: Model predictions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model predictions of habitat use based on survey data from 2006-2010; no specific dosage or duration mentioned.
Study: 27556735
Drug: Map predicting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Map predicting intensity of use by golden eagles during late summer across a ∼2 million‐km2 study area; no specific dosage or duration mentioned.
Study: 17344605
Drug: Computerized pelvis
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized pelvis traction, ultrashort wave, and traditional Chinese medicine iontophoresis
Study: 15695300
Drug: Once-weekly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly oral alendronate (1-2 mg/kg body weight)
Study: 11876712
Drug: Tetracycline-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, tetracycline 500 mg four times daily for 7 days)
Study: 11876712
Drug: Clarithromycin-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily for 7 days)
Study: 12577331
Drug: Composite Salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Salviae Injection (CSI) 0.5 ml/kg by intravenous dripping
Study: 9756307
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined (cc) 2 mg oestradiol valerate and 0.7 mg norethisterone acetate HRT daily
Study: 10151073
Drug: Rhinopront syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinopront syrup (15 g)
Study: 10151073
Drug: Triaminic (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triaminic (commercial standard decongestant)
Study: 10151073
Drug: Rhinopront syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinopront syrup (1 g per year of age)
Study: 30246187
Drug: Supracrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supracrestal implants (SC)
Study: 30246187
Drug: Bone level
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone level implants (BL)
Study: 26330288
Drug: Adjunctive armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive armodafinil 150 mg/day
Study: 25933099
Drug: Adjunctive armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive armodafinil 200 mg/day
Study: 19058484
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (two drops in growing concentrations of 500, 1,000, 2,000, 10,000, and 20,000 biological units)